Investor Relations

Rigel's Mission

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.

Rigel Pharmaceuticals Provides Business Update

View All

Jan 7, 2021 • 7:30 AM EST

Rigel to Present at the 39th Annual J.P. Morgan Healthcare Conference

Dec 4, 2020 • 7:30 AM EST

Rigel Announces Two Posters Highlighting TAVALISSE at the 62nd ASH Annual Meeting & Exposition

Nov 23, 2020 • 7:30 AM EST

Rigel and Medison Announce Health Canada Approval of TAVALISSE®, an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia

January 2021

View Presentation

39th Annual J.P. Morgan Healthcare Conference

View Event View All

Q3 2020

Quarter Ended Sep 30, 2020

Earnings Release

PDF HTML

Audio

Earnings Webcast

Earnings Presentation

PDF

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2019

Investor Contact Information

Company

Rigel Pharmaceuticals, Inc.
1180 Veterans Blvd
South San Francisco, CA 94080